Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
2 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
2
Trials led
0
Active
15
Total enrollment
4
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 3
2
Trials by status
Terminated
2
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant PatientsBMI ≥30Ph 3Terminated13
Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon LiraglutidBMI 35-55Ph 3Terminated2